- Home
- ENTA vs MCRB Comparison
ENTA vs MCRB Comparison
Compare ENTA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- MCRB
- Stock Information
- Founded
- ENTA 1995
- MCRB 2010
- Country
- ENTA United States
- MCRB United States
- Employees
- ENTA N/A
- MCRB N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- MCRB Health Care
- Exchange
- ENTA Nasdaq
- MCRB Nasdaq
- Market Cap
- ENTA 164.6M
- MCRB 165.3M
- IPO Year
- ENTA 2013
- MCRB 2015
- Fundamental
- Price
- ENTA $7.84
- MCRB $18.03
- Analyst Decision
- ENTA Strong Buy
- MCRB Hold
- Analyst Count
- ENTA 5
- MCRB 4
- Target Price
- ENTA $20.20
- MCRB $73.67
- AVG Volume (30 Days)
- ENTA 164.6K
- MCRB 245.0K
- Earning Date
- ENTA 08-11-2025
- MCRB 11-12-2025
- Dividend Yield
- ENTA N/A
- MCRB N/A
- EPS Growth
- ENTA N/A
- MCRB N/A
- EPS
- ENTA N/A
- MCRB 10.22
- Revenue
- ENTA $64,806,000.00
- MCRB N/A
- Revenue This Year
- ENTA N/A
- MCRB N/A
- Revenue Next Year
- ENTA $1.65
- MCRB N/A
- P/E Ratio
- ENTA N/A
- MCRB $1.76
- Revenue Growth
- ENTA N/A
- MCRB N/A
- 52 Week Low
- ENTA $4.09
- MCRB $6.53
- 52 Week High
- ENTA $13.37
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- ENTA 45.61
- MCRB 52.55
- Support Level
- ENTA $7.28
- MCRB $14.22
- Resistance Level
- ENTA $8.86
- MCRB $24.67
- Average True Range (ATR)
- ENTA 0.53
- MCRB 2.08
- MACD
- ENTA -0.18
- MCRB -0.38
- Stochastic Oscillator
- ENTA 29.63
- MCRB 36.48
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.